TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01540396

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary modification and medications
Description: Patients diagnosed with gestational diabetes will receive dietary advice and instruction on blood glucose monitoring from their regular prenatal doctors, consistent with standard of care practices. Medications (glyburide, insulin) will be used as needed to assist with blood glucose control.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary modification and medications
Description: Patients diagnosed with gestational diabetes will receive dietary advice and instruction on blood glucose monitoring from their regular prenatal doctors, consistent with standard of care practices. Medications (glyburide, insulin) will be used as needed to assist with blood glucose control.
Study: NCT02913521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium Gel 1%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voltaren Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01680458

Intervention type: DRUG
Intervention: Fluconazole
Description: Candidiasis infection: The recommended dosage in children is 3 mg/kg once daily.~Cryptococcal infection: The recommended dosage in children is 6 mg/kg once daily. A dosage of 12 mg/kg once daily may be used, based on medical judgment of the patient's response to therapy.~Prophylactic administration for deep mycosis on Hematopoietic stem cell transplantation: The recommended dosage in children is 12 mg/kg once daily.~Absolute doses exceeding 600 mg/day are not recommended.
Study: NCT00492934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human menopausal gonadotrophins
Description: Daily subcutaneous injections, dose 37.5 IU or 75 IU, start on day 2 of the menstrual cycle until ovulation
Study: NCT00447044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Subjects will lift weights with their legs.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: diet orange soda
Description: Subjects drink diet orange soda 3x day for 2 days.
Study: NCT01578499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Brentuximab vedotin intravenous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexarotene
Description: Bexarotene tablets.
Study: NCT02913105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMB763
Description: Hard Gelatin Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hard Gelatin Capsule
Study: NCT01401543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY2452473
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900010
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900010
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900010
Description: Administered orally
Study: NCT02836951

Intervention type: OTHER
Intervention: Withdrawal of blood
Description: Withdrawal of blood

Intervention type: OTHER
Intervention: Withdrawal of blood
Description: Withdrawal of blood
Study: NCT00224406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repertaxin
Description: An initial 'loading dose' of repertaxin was administered over 30 minutes by intravenous infusion followed by a maintenance dose lasting 47.5 hours.The infusion was to start approximately 2 hours prior to the anticipated time of reperfusion and was to continue during the ICU/hospital stay. The study medication was administered as a continuous intravenous infusion into a (high flow) central vein, by an infusion pump adequate to provide reliable infusion rates , as per treatment schedule. Total infusion volume was not to exceed 500 mL/24 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An initial 'loading dose' of placebo was administered over 30 minutes by intravenous infusion followed by a maintenance dose lasting 47.5 hours.The infusion was to start approximately 2 hours prior to the anticipated time of reperfusion and was to continue during the ICU/hospital stay. The placebo was administered as a continuous intravenous infusion into a (high flow) central vein, by an infusion pump adequate to provide reliable infusion rates , as per treatment schedule. Total infusion volume was not to exceed 500 mL/24 hours.
Study: NCT02156063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT100

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03975725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the use of the WitCard
Description: electrocardiogram (ECG)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the use of WitDisplayer
Description: a software to visualize, measure, annotate, comment, archive, and share the different ECGs acquired with the WitCard (ECGW) of different patients.
Study: NCT01506687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health counselling by nurse navigator
Description: Information on colorectal cancer and screening, assistance in selection of screening option and obtaining kit or colonoscopy referral

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual primary care counselling
Description: Usual care health counselling on colorectal cancer and screening options
Study: NCT02389374

Intervention type: DRUG
Group type: OTHER
Intervention: chloroquine
Description: standard dose

Intervention type: DRUG
Group type: OTHER
Intervention: Artemether-lumefantrine combination
Description: standard dose

Intervention type: DRUG
Group type: OTHER
Intervention: Artemether-lumefantrine combination
Description: standard dose

Intervention type: DRUG
Group type: OTHER
Intervention: Primaquine
Description: single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Primaquine
Description: 14 days

Intervention type: DRUG
Group type: OTHER
Intervention: Primaquine
Description: 14 days
Study: NCT03747913

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidative supplementation
Description: Each participant conducts two identical cycling tests, first without and a week later with antioxidative supplementation
Study: NCT01904630

Intervention type: GENETIC
Intervention: gene sequencing
Description: Gene sequencing by exome capture and high throughput sequencing for identification of rare variants
Study: NCT01648192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losmapimod for single dose
Description: Film coated white tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losmapimod for single dose
Description: Film coated white tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losmapimod for single dose
Description: Film coated white tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Losmapimod for single dose
Description: Film coated white tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losmapimod for repeat dose
Description: Film coated white tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Losmapimod for repeat dose
Description: Film coated white tablet
Study: NCT01343966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MABT5102A
Description: Repeating subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MABT5102A
Description: Repeating intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Repeating subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Repeating intravenous infusion
Study: NCT03681184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo by SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumasiran
Description: Lumasiran by SC injection
Study: NCT02149706

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeuroVax
Description: NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA
Study: NCT03681184

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lumasiran
Description: Lumasiran by SC injection
Study: NCT01243177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide:~* Strengths: 50 mg / 100 mg~* Form: tablets~* Dosage: total daily target dose of 200 mg, 400 mg or 600 mg. 1 dose reduction was allowed from either 600 mg to 500 mg or from 400 mg to 300 mg total daily dose~* Duration: up to 118 weeks
Study: NCT02149706

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IFA Incomplete Freund's Adjuvant
Description: IFA Placebo Incomplete Freund's Adjuvant
Study: NCT01243177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine-Controlled Release
Description: Carbamazepine-CR:~* Strengths: 200 mg~* Form: tablets~* Dosage: total daily target dose of 400 mg, 800 mg or 1200 mg. 1 dose reduction was allowed from either 1200 mg to 1000 mg or from 800 mg to 600 mg total daily dose~* Duration: up to 118 weeks
Study: NCT01723020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 232
Description: Given an an oral tablet in escalating doses.
Study: NCT03013985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine U300
Description: Glargine U300 is a new generation long-acting insulin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine U100
Description: Glargine U100 is a long-acting insulin.
Study: NCT04753944

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Probiotic
Description: The evaluation of the influence of a probiotics therapy on mood improvement and the reduction of depressive symptoms in women in the perimenopausal age group.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Patients will be introduced for 5 weeks with placebo consisting of starch, maltodextrins and vegetable protein. The placebo dose is going to be 4 capsules daily. The treatment will be administered two times a day, during breakfast and supper.
Study: NCT04344210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-interventions related to diabetes management and mental well-being
Description: Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period
Study: NCT05672771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Different Mixed Condition (DM)
Description: Participants engage in home-based training on two working memory tasks, both different from those in the target task training. Goal is 10 days of training, with 4 8-min blocks of training each day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Different Single Condition (DS)
Description: Participants engage in home-based training on a working memory task that is different from that in the target task training. Goal is 10 days of training, with 4 8-min blocks of training each day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Same Task (ST) Practice Control
Description: Participants engage in home-based training on the exact same working memory tasks as that in the target task training. Goal is 10 days of training, with 4 8-min blocks of training each day.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-WM Placebo Control (PC)
Description: Participants engage in home-based training on speeded verbal decision, which unlike the target task training, has no memory component. Goal is 10 days of training, with 4 8-min blocks of training each day.
Study: NCT02165826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast Placebo
Description: Roflumilast placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care COPD Treatment
Description: The participant is on standard of care COPD maintenance treatment including LABAs, long-acting anticholinergics, or any combination thereof taken on a constant daily dose within 12 weeks prior to Screening (Visit V0) Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics: Tiotropium, Aclidinium.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care COPD Treatment
Description: The participant is on standard of care COPD maintenance treatment including LABAs, long-acting anticholinergics, or any combination thereof taken on a constant daily dose within 12 weeks prior to Screening (Visit V0) Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics: Tiotropium, Aclidinium.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care COPD Treatment
Description: The participant is on standard of care COPD maintenance treatment including LABAs, long-acting anticholinergics, or any combination thereof taken on a constant daily dose within 12 weeks prior to Screening (Visit V0) Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics: Tiotropium, Aclidinium.
Study: NCT01856517

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02562898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 560, 840, 420, or 280mg, orally once per day - 4 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 560, 840, 420, or 280mg, orally once per day - 4 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 125mg/m2 IV Day 1, 8, and 15 - 4 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 125mg/m2 IV Day 1, 8, and 15 - 4 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 IV Day 1, 8, and 15 - 4 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 IV Day 1, 8, and 15 - 4 week cycle
Study: NCT00565071

Intervention type: DEVICE
Group type: OTHER
Intervention: Field microscopy and Paracheck Pf®
Description: Malaria diagnosis based on microscopy and or Paracheck Pf®. Artemether/Lumefantrine (20mg/120mg) is first-line drug in all arms

Intervention type: DEVICE
Group type: OTHER
Intervention: Field microscopy and Paracheck Pf®
Description: Malaria diagnosis based on microscopy and or Paracheck Pf®. Artemether/Lumefantrine (20mg/120mg) is first-line drug in all arms
Study: NCT04099654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core-Stabilization Exercise
Description: A program consisting of core stabilization exercises and physical activity counseling accompanied by physiotherapists will be applied to the study group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling of physical activity
Description: Only physical activity counseling will be given to the subjects in this group.
Study: NCT01805245

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Stress Reduction
Description: Standard 8-week MBSR program; classes meet for 2.5 hours once weekly The health education control group meets at the same time and for the same amount of time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: Standard 8-week MBSR program; classes meet for 2.5 hours once weekly The health education control group meets at the same time and for the same amount of time
Study: NCT00873327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: piperacillin-tazobactam
Description: 6 doses intravenously at the following doses:~Infants \<32 weeks gestation at birth \< 14 days PNA 100 mg/kg Q8 ≥ 14 weeks PNA 100 mg/kg Q6~Infants ≥32 weeks gestation at birth \< 14 days PNA 100 mg/kg Q6~≥ 14 days PNA 100 mg/kg Q6
Study: NCT04049981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Superpower Glass
Description: The intervention uses the outward-facing camera on the google glasses to read facial expressions and provides social cues within the child's natural environment during usual social interaction and during games accessed via the smartphone application. Participants who receive the Google Glass intervention will be asked to use it for around 20 minutes 3 times a week with their parents.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Superpower Glass
Description: The intervention uses the outward-facing camera on the google glasses to read facial expressions and provides social cues within the child's natural environment during usual social interaction and during games accessed via the smartphone application. Participants who receive the Google Glass intervention will be asked to use it for around 20 minutes 3 times a week with their parents.
Study: NCT04639986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Sacituzumab govitecan 10 mg/kg via IV injection administered on Days 1 and 8 of a 21-day cycle. Subjects will continue to receive study treatment until PD as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin Mesylate Injection
Description: Eribulin is administered by intravenous (IV) following recommended doses and regimens as per approved package inserts.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine Oral Product
Description: Capecitabine is administered orally (PO) following recommended doses and regimens as per approved package inserts.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Injection
Description: Gemcitabine is administered by intravenous (IV) following recommended doses and regimens as per approved package inserts.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine injection
Description: Vinorelbine is administered by intravenous (IV) following recommended doses and regimens as per approved package inserts.
Study: NCT04312542

Intervention type: PROCEDURE
Intervention: Measurement of Biomarkers
Description: Participants will have blood drawn at a 9-month and 12-month visit for the measurement of biomarkers.

Intervention type: PROCEDURE
Intervention: Measurement of Biomarkers
Description: Participants will have blood drawn at a 9-month and 12-month visit for the measurement of biomarkers.
Study: NCT00796627

Intervention type: GENETIC
Group type: SHAM_COMPARATOR
Intervention: Healthy volunteers
Description: Comparison of healthy volunteers to burn wounded volunteers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Burn volunteers
Description: Comparison of burn wounded volunteers to healthy volunteers
Study: NCT02422225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eldith DC-STIMULATOR
Description: Transcranical direct current stimulator (Neuroconn GmbH, Ilmenau, Germany) approved by Conformity European as safe treatment device for stroke patients~tDCS intervention\]~* Intensity: 1.5mA for 20min Device: Neuroconn GmbH, Ilmenau, Germany~* Stimulation site \<Experimental group\>~  * Anode-Anode dual stimulation group Anode: affected pharyngeal motor cortex / Cathode: affected supraorbit Anode: non-affected pharyngeal motor cortex / Cathode: non-affected supraorbit~ * Anode-Cathode dual stimulation group Anode: affected pharyngeal motor cortex Cathode: non-affected pharyngeal motor cortex~ * Single stimulation group Anode: affected pharyngeal motor cortex Cathode: non-affected supraorbit \<Control group\> Sham stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Eldith DC-STIMULATOR
Study: NCT04303442

Intervention type: PROCEDURE
Intervention: TEP
Description: Total extraperitoneal laparoendoscopic hernia repair with one or three skin incisions.
Study: NCT03965780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPIN-SSLED Program
Description: The SPIN-SSLED Program is a 3-month-long (13 sessions) group training program designed to be delivered via videoconferencing to provide information and skills to improve leader support group leaders' confidence and self-efficacy to carry out their leadership roles and reduce the burden on them of leading a support group. Each session is about 90 minutes long and covers one of the 13 modules of the program.~Module topics includes: (1) The Leader's Role; (2) Starting a Support Group; (3) Structuring a Support Group Meeting; (4) Scleroderma 101; (5) Successful Support Group Culture; (6) Managing Support Group Dynamics; (7) Loss and Grief: The support group leader; (8) Loss and Grief in Scleroderma: Supporting group members; (9) Advertising and Recruitment for the Support Group; (10) The Continuity of the Group; (11) Supporting Yourself as a Leader; (12) Remote Support Groups; and (13) Transitions in Support Groups.
Study: NCT01071837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG101
Description: 400mg weekly as intravenous infusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood drawing
Description: Blood drawings, e.g. for safety labs, abdominal ultrasound, ECG. Re-Irradiation is not considered a study procedure, but standard of care (inclusion criterion)
Study: NCT03674762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microgrooved dental implants
Description: Dental Implant placement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microgrooved dental implants
Description: Dental Implant placement
Study: NCT04266847

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: monofocal IOL,bifocal IOL,or trifocal IOL
Description: phacoemulsification and implantation of IOL.IOL may be monofocal IOL,bifocal IOL,or trifocal IOL
Study: NCT04585100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FM101 tablet
Description: Bio-equivalent test (tablet vs oral solution)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FM101 oral solution
Description: Bio-equivalent test (tablet vs oral solution)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo BID for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FM101 150 mg
Description: FM101 (150 mg) BID for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FM101 300 mg
Description: FM101 (300 mg) BID for 28 days